Quantcast

Latest Menorrhagia Stories

2011-05-04 08:00:00

WASHINGTON, May 4, 2011 /PRNewswire/ -- Cyclic heavy menstrual bleeding (HMB) has been reported to significantly impact a woman's ability to get uninterrupted sleep which can often lead to daytime fatigue and irritability.(1) According to a recent retrospective analysis of the 6-cycle pivotal trial that supported product approval, women taking LYSTEDA® (tranexamic acid) Tablets, 3.9 g/day, experienced a 0.99 mean reduction in the number of sleep interruptions over...

2011-05-04 07:02:00

BEDFORD, Mass., May 4, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is featuring new, minimally invasive technologies in surgical, diagnostic and skeletal health at the 59th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in Washington, DC...

2011-05-02 05:45:00

PARSIPPANY, N.J., May 2, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. commercial launch of Generess(TM) Fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods. (Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO) Generess Fe...

2011-03-21 08:00:00

WASHINGTON, March 21, 2011 /PRNewswire/ -- Millions of American women suffer from cyclic heavy menstrual bleeding (HMB), and a recent national survey of more than 1,600 nurse practitioners revealed that this condition has a considerable negative impact on patients' health, lifestyle and even employment. Yet very few patients report their symptoms or request professional help, or they delay reporting their HMB to a medical professional from five months to more than one year, according to...

2011-01-19 13:51:42

Tranexamic acid (TXA), a drug used to treat heavy menstrual periods, could save the lives of tens of thousands of bleeding accident victims each year and reduce combat deaths, say Cochrane researchers. The researchers carried out a systematic review of trials examining the effectiveness of tranexamic acid (TXA) in patients with bleeding after severe injury. TXA is an inexpensive drug that reduces clot breakdown. It has been used for many years to reduce heavy menstrual bleeding and is often...

2011-01-07 06:00:00

BEDFORD, Mass., Jan. 7, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN...

2010-12-22 15:26:00

MORRISTOWN, N.J., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product - the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy. Watson's new...

2010-12-01 07:00:00

MORRISTOWN, N.J., Dec. 1, 2010 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), announced today that ella® (ulipristal acetate) 30 mg, a novel oral emergency contraceptive, is now available for patients by prescription in the U.S. ella® was approved by the U.S. Food and Drug Administration (FDA) as safe and effective in helping to prevent unintended pregnancy for up to five days after unprotected intercourse (UPI) or a known contraceptive...

2010-11-22 07:00:00

SAN DIEGO, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. "The previously announced improvements across all endometriosis-associated pain domains, during the eight week placebo controlled portion of...

2010-11-09 14:28:00

BEDFORD, Mass., Nov. 9, 2010 /PRNewswire/ -- Booth #410 -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will showcase its Total Office Solution(TM) at the American Association of Gynecologic Laparoscopists (AAGL) 39th Annual Global Congress of Minimally Invasive Gynecology, November 8-12, 2010, at Caesars Palace...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'